Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

NCT05164458 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: IBI 308 injection
DRUG: IBI 389 Injection

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.